Patient characteristics (N = 48)
| Variable . | Third-line TKI . | |
|---|---|---|
| Dasatinib (n = 34) . | Nilotinib (n = 14) . | |
| Median age, y (range) | 53 (18-70) | 49 (19-70) |
| Stage at start of imatinib | ||
| CP | 29 (85%) | 10 (72%) |
| AP | 5 (15%) | 3 (21%) |
| BP | 0 | 1 (7%) |
| Time on imatinib, mo | 30.2 | 43 |
| Best response to imatinib | ||
| MMR | 4 | |
| CCyR | 4 | |
| mCyR | 5 | 5 |
| CHR | 7 | 3 |
| NR | 1 | |
| NA | 14 | 5 |
| Failure to imatinib | ||
| Resistance | 34 | 13 |
| Intolerance | 1 | |
| Imatinib dose, mg | ||
| 400 | 26 (76%) | 11 (79%) |
| More than or equal to 600 mg | 8 (24%) | 3 (21%) |
| Stage at start of second-line TKI | ||
| CP | 17 (50%) | 8 (57.2%) |
| AP | 10 (29%) | 3 (21.4%) |
| BP | 7 (21%) | 3 (21.4%) |
| Mutations (second TKI) | 20 | 4 |
| Time on second TKI, mo | 7.7 | 10.3 |
| Best response to second-line TKI | ||
| MMR | 5 | |
| CCyR | 3 | 2 |
| PCyR | 4 | 1 |
| mCyR | 11 | 5 |
| CHR | 10 | 4 |
| NR | 1 | 2 |
| Failure to second TKI | ||
| Resistance | 30 (88%) | 9 (64%) |
| Intolerance | 4 (12%) | 5 (36%) |
| Stage at third-line TKI | ||
| CP | 16 (47%) | 9 (64.3%) |
| AP | 8 (24%) | 2 (14.3%) |
| BP | 10 (29%) | 3 (21.4%) |
| Mutation at third TKI | 24 (71%) | 8 (57%) |
| Stage at start of third-line therapy | ||
| CP | 16 (47%) | 9 (64%) |
| AP | 8 (26%) | 2 (14%) |
| BP | 10 (29%) | 3 (21%) |
| Interval treatment (between second- and third-line TKI) | ||
| Not treated | 25 (74%) | 7 (50%) |
| Treated | 9 (26%)* | 7 (50%)† |
| Starting dose ofthird-line TKI | ||
| QD dosing | 140 mg, 9 (26%), 100 mg, 3 (9%), 50 mg, 1 (3%) | 800 mg, 2 (14%), 400 mg, 1 (7%) |
| BID dosing | 70 mg, 15 (44%), 50 mg, 5 (15%), 120 mg, 1 (3%) | 400 mg, 11 (79%) |
| Variable . | Third-line TKI . | |
|---|---|---|
| Dasatinib (n = 34) . | Nilotinib (n = 14) . | |
| Median age, y (range) | 53 (18-70) | 49 (19-70) |
| Stage at start of imatinib | ||
| CP | 29 (85%) | 10 (72%) |
| AP | 5 (15%) | 3 (21%) |
| BP | 0 | 1 (7%) |
| Time on imatinib, mo | 30.2 | 43 |
| Best response to imatinib | ||
| MMR | 4 | |
| CCyR | 4 | |
| mCyR | 5 | 5 |
| CHR | 7 | 3 |
| NR | 1 | |
| NA | 14 | 5 |
| Failure to imatinib | ||
| Resistance | 34 | 13 |
| Intolerance | 1 | |
| Imatinib dose, mg | ||
| 400 | 26 (76%) | 11 (79%) |
| More than or equal to 600 mg | 8 (24%) | 3 (21%) |
| Stage at start of second-line TKI | ||
| CP | 17 (50%) | 8 (57.2%) |
| AP | 10 (29%) | 3 (21.4%) |
| BP | 7 (21%) | 3 (21.4%) |
| Mutations (second TKI) | 20 | 4 |
| Time on second TKI, mo | 7.7 | 10.3 |
| Best response to second-line TKI | ||
| MMR | 5 | |
| CCyR | 3 | 2 |
| PCyR | 4 | 1 |
| mCyR | 11 | 5 |
| CHR | 10 | 4 |
| NR | 1 | 2 |
| Failure to second TKI | ||
| Resistance | 30 (88%) | 9 (64%) |
| Intolerance | 4 (12%) | 5 (36%) |
| Stage at third-line TKI | ||
| CP | 16 (47%) | 9 (64.3%) |
| AP | 8 (24%) | 2 (14.3%) |
| BP | 10 (29%) | 3 (21.4%) |
| Mutation at third TKI | 24 (71%) | 8 (57%) |
| Stage at start of third-line therapy | ||
| CP | 16 (47%) | 9 (64%) |
| AP | 8 (26%) | 2 (14%) |
| BP | 10 (29%) | 3 (21%) |
| Interval treatment (between second- and third-line TKI) | ||
| Not treated | 25 (74%) | 7 (50%) |
| Treated | 9 (26%)* | 7 (50%)† |
| Starting dose ofthird-line TKI | ||
| QD dosing | 140 mg, 9 (26%), 100 mg, 3 (9%), 50 mg, 1 (3%) | 800 mg, 2 (14%), 400 mg, 1 (7%) |
| BID dosing | 70 mg, 15 (44%), 50 mg, 5 (15%), 120 mg, 1 (3%) | 400 mg, 11 (79%) |
MUD indicates matched unrelated donor transplantation; QD, once daily; BID, twice daily; NA, not applicable; and TKI, tyrosine kinase inhibitors.
In dasatinib third-line group, interval treatments included 6 imatinib, 2 HyperCVAD, 1 MUD, 1 INNO-406, 1 KOS-953, and 1 MK-0457.
In nilotinib third-line group, interval treatments included 4 SKI-606, 1 INNO-406, 1 Ara-C/idarubicin/imatinib, and 1 imatinib.